BIOLOG-ID
The members of the Supervisory Board of Biolog-id elected Jean-Luc Bélingard as Chairman of the Supervisory Board of the company. He succeeds to its founder, Jean-Claude Mongrenier, who will assume the vice-presidency. This appointment comes into effect on January 1st , 2021.
Biolog-id has developed unique expertise in connected healthcare solutions and offers a breakthrough innovation that makes the life cycle of sensitive therapeutic products (red blood cell concentrates, platelets, plasma, chemotherapy preparations) more reliable, and secures their administration to patients.
Jean-Luc Bélingard is a seasoned industry leader with an international career in the pharmaceutical, life sciences and diagnostics sector. He comes with 40 years of experience with some of the largest pharmaceutical companies, notably at Roche where he was a member of the Group Executive Committee (Basel, Switzerland). Since 2011, he has served as CEO and then Chairman of bioMérieux before taking on, in 2018, the Vice-Presidency of Institut Mérieux.
"It is an honor and a responsibility for me to join and support Biolog-id in a new stage of its development. Biolog-id is a company with a promising future. It patented a connected solution, Medical Device certified, which offers great added value in terms of public healthcare, with significant economic and social impacts. It makes it possible to strengthen the safety of medical procedures, improve the working conditions of healthcare professionals, reduce operational costs and prevent the loss of sensitive health products. This set of added values is a guarantee of quality and safety for patients and healthcare establishments. By accepting this mandate as Chairman of the Supervisory Board, I hope, along with the management team and employees, to contribute to the success of this innovative company”, declares Jean-Luc Bélingard.
"As the founder of the company, I am happy to hand over my functions to Jean-Luc Bélingard, with whom I share the same vision of the company, based on humanist values. Biolog-id will benefit from its extensive experience in the pharmaceutical industry and its governance skills. In particular, he will be responsible for leading the introduction of Biolog-id on the Nasdaq, its listing being planned as of 2022 ", announces Jean-Claude Mongrenier.
"The appointment of Jean-Luc Bélingard as Chairman of the Supervisory Board will allow Biolog-id to benefit from a high-level leadership executive with an indisputable influence. This is an important appointment for the international development of the company and for its upcoming IPO. I am convinced that he will be able to capitalize on this flagship of the FrenchTech 120 to make it go through new major stages, "confirms Jacques Simonnet, founder of the Xerys Group which has already funded Biolog-id up to about fifty million euros and is preparing a capital increase of more than 20 million euros.
About Biolog-id
Biolog-id has designed an intelligent and patented solution for the management and traceability of sensitive healthcare products (red blood cell concentrates, plasma, platelets, chemotherapy preparations), in order to optimize their supply chain from donor to patient. Present in North America, Europe, the Middle East, India and the Asia-Pacific region, Biolog-id has about a hundred employees around the world. The Biolog-connect® solution is protected by more than 100 international patents. Biolog-id is the property of its founder and the Xerys Funds.
Web site: www.biolog-id.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210104005413/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Taylor Wessing Diversifies Its International Strategy17.12.2025 15:05:00 CET | Press release
International law firm Taylor Wessing is set to diversify its strategy within its international alliance, in order to push international growth and innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251217415857/en/ Dr. Oliver Bertram, Global Co-Chair at Taylor Wessing The English part of the partnership is seeking a merger with US law firm Winston & Strawn and would – depending on a corresponding partner decision, which is still pending – leave the Taylor Wessing alliance at the end of April 2026. Both parties wish to continue their successful joint international client work unchanged. Therefore, collaboration between Taylor Wessing and future Anglo-American firm Winston Taylor will continue seamlessly based on a cooperation agreement, ensuring that clients will not experience any change in their collaboration with Taylor Wessing. With the firm’s new open strategy, Taylor Wessing equally meets the strategic requirem
ISACA to Lead Global Credentialing for CMMC Cybersecurity Framework as International Cyber Readiness Standards Rise17.12.2025 15:00:00 CET | Press release
ISACA appointed to certify professionals assessing organisations against the US Department of War’s (DoW) Cybersecurity Maturity Model Certification (CMMC) programme.New requirements mean that all global businesses supplying to US DoW will need to be compliant with this framework, impacting over 200,000 organisationsAppointment supports global demand for consistent, verifiable cyber maturity amid escalating cyber threats and growing assessor shortages.The Cyber AB remains the official accreditation body for the CMMC programme, authorizing the CAICO and other CMMC ecosystem parties As cyber threats escalate and governments raise expectations around operational resilience, ISACA has been appointed to lead the global credentialing programme for the U.S. DoW’s Cybersecurity Maturity Model Certification (CMMC) program. The appointment positions ISACA – the international association for cybersecurity, audit and digital trust – as the exclusive CMMC Assessor and Instructor Certification Organ
ASN Bank Signs a Contract With HCLTech to Accelerate Digital Transformation and Enhance Customer Experience17.12.2025 14:43:00 CET | Press release
HCLTech, a leading global technology company, today announced that it has been selected as a strategic partner by ASN Bank (formerly de Volksbank), the fourth-largest retail bank in the Netherlands. As part of its new strategy ‘Simplify and Grow’, ASN Bank aims to modernise and standardise its IT architecture, which will involve consolidating IT services, simplifying the vendor landscape and building a future-ready organisation. Under the multi-year agreement, HCLTech will support ASN Bank’s enterprise applications, and streamline services through a distributed delivery model to enhance efficiency and customer experience. Michel Ruijterman, Chief Information Officer, ASN Bank: “By signing this agreement , HCLTech’s proven track record in delivering scalable, innovative solutions tailored to the financial services sector means we can now confidently press on with streamlining our business by reducing the number of existing products and aligning the underlying processes and systems under
Riskified Announces Ascend 2026: “Intelligence in Motion” for the Next Era of Ecommerce17.12.2025 14:30:00 CET | Press release
From North America to the Asia-Pacific, Ascend 2026 will bring together leaders from the fraud and risk management community to define innovation-led ecommerce growth strategies Riskified (NYSE:RSKD), the leader in AI fraud and risk management for ecommerce, has announced that its premier global summit Ascend will once again be held as a global event series in 2026. Kicking off with North America (May) and continuing to Europe (June), Australia (August), China (September), and Japan (October), Ascend will convene each region’s largest merchants, industry experts, and technology leaders to discover the latest AI advancements and innovative strategies to propel ecommerce success. “Having pioneered using AI to fight ecommerce fraud and policy abuse over the past 10+ years, it’s equally exhilarating as it is concerning to witness the dramatic impact AI and agentic commerce are making on our industry. As risk grows more complex and shopper expectations rise, fraud teams and customer experie
Sinovac: Antigua Court Makes Interim Order Giving Board Control of the Company until the Trial of the Disputed 2025 Shareholder Meeting17.12.2025 13:00:00 CET | Press release
Sinovac Biotech Ltd. (NASDAQ: SVA) (SINOVAC or the Company), a leading provider of biopharmaceutical products in China, today announced that the Antigua High Court has ordered that the directors Mr. Simon Anderson, Mr. Shan Fu, Mr. Shuge Jiao, Mr. Yuk Lam Lo, Mr. Yumin Qiu, Mr. Yu Wang, Mr. Andrew Y. Yan and Mr. Yin Weidong (collectively, the Board), will comprise the Board of the Company until the trial listed in late April/early May 2026. The Antigua High Court decision arises from a hearing that took place on 27 October 2025, at which applicants SAIF Partners IV L.P., OrbiMed Partners Master Fund Limited and 1Globe Capital LLC each sought injunctions to confirm the composition of their respective favoured Boards, pending determination of a dispute over the outcome of the Company’s Special Shareholders Meeting on 8 July 2025 (the SSM Dispute). The hearing of the SSM Dispute has been scheduled to take place in the Antigua High Court in late April/early May 2026, with judgment to be de
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom